HC Wainwright reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a report released on Wednesday,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for ImmunityBio's Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.48) EPS.
IBRX has been the topic of a number of other research reports. BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They set a "buy" rating and a $6.00 price objective on the stock. D. Boral Capital restated a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $12.19.
Get Our Latest Research Report on ImmunityBio
ImmunityBio Stock Down 0.4 %
Shares of IBRX stock traded down $0.01 on Wednesday, reaching $2.47. The company had a trading volume of 4,693,391 shares, compared to its average volume of 5,816,220. The business's 50-day moving average is $2.95 and its 200 day moving average is $3.50. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The stock has a market capitalization of $2.11 billion, a PE ratio of -2.68 and a beta of 0.51.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. On average, sell-side analysts forecast that ImmunityBio will post -0.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ImmunityBio
Institutional investors and hedge funds have recently made changes to their positions in the stock. Stephens Inc. AR bought a new stake in ImmunityBio in the fourth quarter valued at approximately $26,000. Thrive Wealth Management LLC bought a new stake in shares of ImmunityBio in the 1st quarter valued at $30,000. Cibc World Markets Corp acquired a new stake in shares of ImmunityBio during the fourth quarter worth $35,000. Maia Wealth LLC bought a new position in ImmunityBio during the fourth quarter worth $37,000. Finally, GF Fund Management CO. LTD. acquired a new position in ImmunityBio in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Read More
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
